Medindia LOGIN REGISTER
Medindia
Advertisement

Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction

by Kathy Jones on March 19, 2013 at 9:23 PM
 Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction

The European Commission has approved the use of ocriplasmin for treating vitreomacular traction (VMT) in the European Union.

Ocriplasmin has been developed by ThromboGenics in collaboration with Novartis and will be sold under the brand name Jetrea. VMT is an age-related and progressive condition which could result in severe eye damage.

Advertisement

The drug has been approved for treating VMT when it is associated with a macular hole with a diameter of 400 m or less.

ThromboGenics will be paid 45 million by Alcon, a subsidiary unit of Novartis, with a similar payment to be made with the first sale of the drug. Around 250,000-300,000 patients in Europe are reported to suffer from VMT with the current treatment involving a 'watchful process' until the patient is eligible for surgery.

Source: Medindia
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Drug News

Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests